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Proliferative autoimmune glomerulonephritis: A model for autoim-
mune glomerulonephrltls in humans. Some forms of glomerulonephritis
(GN) in humans appear consequent to autoimmunity, Experimental
autoimmune ON (EAG) has been described in sheep, but attempts to
develop EAG in other mammals have resulted only in antibody and
proteinuria but no ON. We have developed a model of EAG in an
inbred mammalian species to further study pathogenetic mechanisms.
We immunized Brown Norway (BN) and Wistar-Kyoto (WKY) rats
with glomerular basement membrane (GBM) or collagenase solubilized
GBM (csGBM). Circulating and bound anti-GBM antibody developed
in all rats. Only interstitial nephntis occurred in BN rats despite
amounts of glomerular and serum anti GBM antibodies similar to WKY
animals. One hundred percent of WKY rats immunized with csGBM/
acid developed reproducible severe GN at two to three weeks with
proteinuria and decreased kidney function which progressed to glomer-
ulosclerosis and interstitial fibrosis. Antigen in acid was a requisite for
induction of EAG. EAG rats had positive tests for delayed type
hypersensitivity, their T cells underwent antigen specific transforma-
tion, and T cells and macrophages were present histologically. Passive
transfer of EAG serum to naive rats resulted in fixation to recipient
GBM but no proteinuria or ON. This new model of EAG in rats appears
dependent on genetic factors, may involve cellular immunity in patho-
genesis, requires exposure of the nephritogenic antigen, and is highly
similar to rapidly progressive ON in humans.
Glomerulonephritis (GN) is an inflammatory process charac-
terized by proliferation of endogenous cells usually accompa-
nied by an influx of exogenous inflammatory cells [1]. In
humans, ON may be associated with antibodies directed toward
and deposited on the glomerular basement membrane (GBM),
result from deposition of circulating soluble immune com-
plexes, or occur without detectable immune deposits [2].
Various experimental animal models have been employed to
study the pathogenesis of GN. These involve: (1) administration
of heterologous antibodies directed to constituents of the kid-
ney, (2) passive infusion of immune complexes, (3) fortuitous
deposition of preformed antigen-antibody complexes in the
glomerulus, or (4) in situ mechanisms. These models have
provided us with a wealth of information about mechanisms of
inflammation in the glomerulus. However, their relevance to
human disease, which obviously cannot derive by most of these
Received for publication October 19, 1992
and in revised form March 25, 1993
Accepted for publication March 25, 1993
© 1993 by the International Society of Nephrology
mechanisms, remains to be ascertained by models in which true
autoimmune ON develops.
It is likely that most, if not all, forms of human GN develop
through loss of tolerance to autologous antigens except in those
situations, such as postinfectious GN, where an obvious source
of exogenous antigen for immune complex formation is present
[3]. The experimental counterpart, experimental autoimmune
GN or Steblay nephritis (EAG) was first described in sheep
three decades ago [4]. Multiple immunizations of animals with
whole glomeruli resulted in formation of antibody which fixed
to GBM, and the development of proteinuria, proliferative GN
and uremia. This model appears relevant to human disease
since no preformed antibodies or antigens are administered and
the animal develops an immune process against its own kid-
neys. Although numerous mammals immunized with multiple
types and doses of glomeruli develop antibody to basement
membrane, only sheep reliably and predictably develop prolif-
erative GN [5—13]. The present report describes a new model of
severe proliferative autoimmune GN quite similar to GN in
humans.
Methods
Animals
Male, Brown Norway (BN) and Wystar-Kyoto (WKY) rats
weighing 200 g were obtained from Charles River Laboratories.
Animals were maintained in the Comparative Medicine quarters
on standard diets and were studied after one to two weeks of
acclimatization.
Preparation of GBM
Bovine kidneys from a local abattoir were frozen at —70°C
until used. They were thawed at 4°C in phosphate buffered
saline (PBS), the cortices separated from the medullae, minced,
and pressed through sieves, 40, 80, and 140 mesh, respectively
[14]. Whole glomeruli were collected on a 200 mesh sieve.
These were washed extensively in PBS at 4°C. Glomerular
preparations were examined by phase contrast microscopy and
were 95% pure glomeruli. To prepare GBM for immunization
and digestion with collagenase, whole glomeruli were sonicated
on ice using a Branson sonicator on high setting for 30 seconds
at a time and preparations examined for disruption of glomeruli
[14]. Portions of GBM were then digested with type VII
collagenase (Sigma Chemical Corp, St. Louis, Missouri, USA).
Digested GBM was prepared by mixing bovine glomeruli in Tris
HC1 buffer, pH 7.4 with 0.01 M CaCl2 and 6.5 mg collagenase at
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37°C for 22 hours and dialyzing the supernatant against deion-
ized water. In some experiments, human GBM was prepared in
a similar fashion and produced identical lesions.
Immunizations
All animals received 0.5 ml of 10 x 1010 Bordetella pertussis
(BP) organisms per ml intraperitoneally once (Dilco Laborato-
ries, Detroit, Michigan, USA). In the first experiment animals
were divided into three groups. All were immunized once.
Group I received intraperitoneally 2 mg of bovine GBM
(BGBM) prepared by sonication of whole glomeruli. Group II
received 2 mg of BGBM suspended in PBS and emulsified with
CFA in one foot pad. Group III was immunized with 20 sg of
collagenase solubilized BGBM (csBGBM) dissolved in PBS
made 0.1 M in acetic acid with CFA in one foot pad. Controls
were immunized by the identical protocols but omitting antigen.
Histopathology
Light microscopy. Tissue was fixed in 10% buffered formalin,
embedded in paraffin, and serially sectioned 3 tm in thickness.
Alternate sections were stained with periodic acid-Schiff re-
agent (PAS) and hematoxylin eosin (H&E). Kidneys sections
were assessed qualitatively without knowledge of study group
or type of immunization schedule [15].
Immunofluorescence microscopy. Immunofluorescence stud-
ies of kidney tissue were performed using commercial mono-
specific fluorescein labeled antisera to rat IgG, C3, and fibrin-
ogen [15]. The intensity of deposits was semiquantitatively
graded from 0 to 4+ as described [14, 15].
Phenotypic analysis. Tissue sections of rats with histologic
GN from Experiment 1 were examined by indirect immunoflu-
orescence using monoclonal antibodies (MAb) to rat leukocyte
antigens (Accurate Chemical and Scientific Corporation, West-
bury, New York, USA). The MAb were: W3/13 (pan T cell);
W3/25 (CD4, T helper cell); MRC OX-8 (CD8, T suppressor
cell), MRC OX-i and OX-22 (CD4S, high molecular wt form of
leukocyte common antigen); OX-33 (B cell), ED-i (macro-
phage) and MRC OX-6 (Ia antigen, macrophage). In addition,
sections were stained with OX-7, MAb to thymus/mesangial
cells to assess mesangial expansion. Description of fluores-
cence findings was done blindly without knowledge of the
experimental groups. In a separate experiment, EAG and
control CFA rats were sacrificed at weekly intervals from 0
through eight weeks, and kidney sections stained by immuno-
peroxidase and MAb described above [14]. Sections were
evaluated blindly without knowledge of histologic scores or
urine protein.
Electron ,nicroscopy. One millimeter cubes of renal cortex
were placed directly into 2% glutaraldehyde paraformaldehyde
buffer for 24 hours then in cacodylate buffer [161. They were
post-fixed in 2% osmium tetroxide and serially dehydrated in
ethanol. Blocks were embedded in Araldite or Poly-bed 812
with DDSA and NMA (Polysciences, Warrenton, Pennsylva-
nia, USA) and thin sections cut with a Porter Blum ultrami-
crotome, stained with lead citrate and examined with a Zeiss
9S2 electron microscope.
Biochemical studies. Serum creatinines were determined by
the Jaffè method using a standard curve for each determination.
Animals were placed in metabolic cages and 24-hour urine
samples were collected for total urinary protein (TUP) deter-
minations. The latter were done using 3% sulfosalicylic acid
with bovine serum albumin as a standard [15].
Delayed type hypersensitivity reaction (DTH). To assess the
development of DTH reactions to the immunogen in immunized
rats, 20 pi of csBGBM or vehicle, (PBS/0.l M acetic acid), were
administered intradermally in the right and left ears, respec-
tively [17]. The difference in thickness of the ears before and 24
or 48 hours after antigen was determined with a Fowler spring
loaded micrometer and expressed in inches. Rats immunized
once with keyhole limpet hemocyanin (KLH) 100 pg in CFA
served as positive controls [14].
Preparation of mononuclear cells and blast transformation
studies. Spleens were harvested aseptically and kept in cold
RPM! 1640 supplemented with 2 mM glutamine, 0.15 M HEPES
buffer, penicillin G, streptomycin (100 U/ml each) plus sodium
pyruvate (2 mM) and mercaptoethanol (2 X i0 M, Sigma) [18].
Five percent fetal calf serum (FCS) was added to media.
Spleens were minced and passed through stainless steel sieves
using glass pestles. Cells were collected in RPMI with antibiot-
ics in siliconized beakers. Cells were layered on Lymphopep
(Nygaard Co, Norway) and centrifuged at 300 x g for 20
minutes. Cells were removed and washed three times in RPM!
1640. Cells were assessed for viability by trypan exclusion and
10 pi of cell suspension were added to 200 1.d of medium plus or
minus antigen or mitogen for culture in 300 1.d U-bottom
microtissue culture plates. The final number of cells was 5 X
104/well. Con A was used as concentration of 4 sg/ml as a
positive control. All cultures were incubated at 37°C in a humid
5% C02/air incubator for 72 hours. Cells received 1 Ci of
3H-thymidine (6.7 Ci mmol sp act) in 20 d of medium and were
cultured for an additional 16 hours. Blast transformation studies
were done with 10 to 100 g/ml csBGBM for three and five
days, KLH immunized rat cells were cultured with 50 pg/ml
KLH for three days. Cultures were harvested by glass fiber
filters on a cell harvester and radioactivity counted in a Beck-
man liquid scintillation counter model S-230. Each data point
was run in quadruplicate, and counts were corrected for back-
ground. Data are expressed as the stimulation index (SI), the
ratio of test-to-medium counts.
Antibody assays. Sera from recipient animals were examined
by indirect immunofluorescence for circulating anti-GBM anti-
bodies and by ELISA using Immulon II plates (Dynatech
Laboratories mc, Alexandria, Virginia, USA) coated with
collagenase digested bovine, rat, or human GBM 10 sg/ml [14,
18]. Controls included buffer alone, blanks without second
antibody, and omission of GBM antigen. Known positive and
negative sera were run.
Experimental plan
Experiment 1—Pilot study. Six rats each of BN and WKY for
each of the three groups (I, II, and III) were immunized with
GBM antigen. Controls as described were used for each group.
TUP was obtained prior to the immunization and at biweekly
intervals thereafter. Open renal biopsies were obtained at three
weeks after the initial immunization and at eight weeks in
remaining animals. Sera were examined at two and four weeks
for the presence of circulating antibody and for serum creati-
nine. Animals were sacrificed after the eighth week when the
last quantitative TUP had been determined.
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Table 1. GBM immunization of BN and WKY rats
Group
Rat
strain N
Antibody
response TUP Sr
Histology
mt GN
I BN 5 + ni nI 3+ 0
WKY 6 + ni nl 0 0
II BN 5 + ni nl tr-I+ 0
WKY 6 + ni nI 0 0
III BN 5 + ni nI 2-3+ 0
WKY 5 + t 0 1-3+
Three control animals for each study group (18 total rats) received identical immunization regimens without antigen; tissue was obtained 3 weeks
after single immunization. Regimens were: Group I, bovine GBM, 2 mg in BP; Group II, bovine GBM, 2 mg in CFA and BP; and Group III,
csBGBM in acid, 20 g in CFA and BP. Abbreviations are: TUP, total urinary protein; Sçr,serum creatinine; Int, interstitial nephritis; GN,
glomerulonephritis; nI, normal; BP, Bordetella pertussis intrapertioneally; and CFA, complete Freund's adjuvant, given in one foot pad.
Experiment 2—Serial studies. In the second set of experi-
ments 24 WKY rats were immunized with csBGBM antigen
once using the same immunization protocol and followed seri-
ally with urinary proteins every other week. Sixteen animals
received csBGBM and eight control rats received CFA and BP
without antigen. Four different subsets of antigen recipient
animals underwent open renal biopsy at weekly intervals for
seven weeks for the purpose of serial determinations of histo-
logic changes. Another set of four animals each was bled at
weekly intervals for serial determination of anti-GBM antibody
titers and serum creatinine.
Experiment 3—The influence on disease production of anti-
gen iii acid. In this study we tested the hypothesis that
suspension of antigen in acid was a requisite for EAG induction.
WKY rats were immunized exactly as described using digested
GBM at pH 7.2 and followed for eight weeks. Controls were
similarly immunized without antigen.
Experiment 4—Studies of in vitro cellular immunity. We
postulated that cellular immunity may be involved in produc-
tion of EAG in our model. We therefore sought evidence for the
presence of cellular immunity to the immunogen. In this exper-
iment an additional group of WKY rats was immunized with
bovine or human csGBM, 20 g as described above, given once
and mononuclear cells were then harvested for in vitro blast
transformation studies as described.
Experiment 5—Passive transfer studies. Attempts were made
to transfer EAG from nephritic to naive rats. Serum from EAG
rats containing high titer anti-GBM antibody was purified by the
caprylic acid method [19]. Naive rats received 1, 10, or 60 mg
i.v., respectively, and were followed for four weeks with
weekly urine protein determinations.
Experiment 6—Glomerular bound anti-GBM antibody. To
assess the amount of glomerular bound rat IgG, we used
kidneys from additional controls, EAG WKY rats, and BN rats
immunized with the same protocol and harvested at the same
time (onset of proteinuria, 4 weeks). Glomeruli were isolated by
differential sieving, counted, eluted with acid into the same
volume/kidney, and the anti-GBM content determined by
ELISA against GBM antigen [5, 14]. The anti-GBM activity of
glomerular eluates was expressed in OD units relative to the
number of glomeruli.
Statistical analysis. Data are presented as mean and standard
error of the mean. Where appropriate, data were analyzed by
the Student's t-test and analysis of variance.
Results
Experiment 1—EAG in BN and WKY rats
All of the BN and WKY rats developed circulating antibodies
to human, rat, and bovine GBM beginning two to three weeks
after the initial immunization. The development of antibodies
was not correlated with the strain of animals or to the type of
immunization (Table 1). Renal tissue was obtained in all animals
three weeks after the initial immunization. By immunofluores-
cence rat IgG was deposited along the GBM and tubular
basement membrane (TBM) in all rats immunized with GBM
regardless of the immunization schedule. The deposits were
present in an uninterrupted linear pattern without granularity.
The GBM deposits were of slightly greater intensity than those
along the TBMs. No abnormal quantities of complement were
detected in any of the specimens. Staining for fibrinogen
showed focal and segmental glomerular deposits only in group
III WKY rats immunized with csBGBM in acid. None of the
other groups of rats and none of the BN rats immunized in a
similar fashion had any fibrin deposits in any of the glomeruli.
By light microscopy, all BN rats immunized with GBM
showed an acute interstitial nephritis. Multinucleated giant
cells, and multi-focal and diffuse mononuclear cell infiltrates
were seen, but glomeruli were normal in all BN animals. In
groups I and II WKY rats no histologic abnormalities were
present. In contrast, all group III WKY rats immunized with
csBGBM in acid showed a proliferative and exudative GN at
the three week biopsy. The intensity of the GN ranged from ito
3 + with two rats graded as 1+, one rat as 2+, and two rats as
3+ GN. Crescents were present in many of the animals.
No abnormal urinary protein was present in any of the
animals at the baseline determination, or two weeks after
immunization. At week four the two remaining animals in the
WKY group III had 54 and 77 mg, respectively, of proteinuria.
At week six these two animals had 123 and 115 mg of protein.
The other animals in WKY group III suffered anesthetic deaths
during the biopsy at week 3. None of the other animals in
groups I or II and none of the BN rats in group III developed
any abnormal proteinuria by eight weeks at which point animals
were all sacrificed. In the eighth week the two remaining WKY
group III rats had 59 and 252 mg 24-hour urine protein excretion
respectively. Serum creatinine values were normal in all ani-
mals examined except for the two WKY animals in group III
which had serum creatinines of 4.0 and 1.7 mg/dl at sacrifice.
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Fig. 1. Time course of appearance of circulatiag antibody to GBM in
WKY rats immunized once with 20 sg csBGBM in acid. (O---O) Titers
at sacrifice for rats immunized by identical protocol but at pH 7.2 is
given in the bar graph (n).
Experiment 2—Serial studies of EAG in WKY rats. When the
results of the first set of experiments indicated that no prolifer-
ative GN or abnormal proteinuria developed in any of the
animals except those immunized with csBGBM in acid, a
second set of experiments was done to study the chronology of
the lesion in more detail.
Serial examinations for the development of circulating anti-
bodies to GBM revealed no evidence of antibody at week 1 and
barely detectable levels at week 2. However, thereafter the titer
of circulating antibody rose rapidly (Fig. 1). Circulating anti-
body against rat, human, and bovine GBM antigen was present
by indirect immunofluorescence and by ELISA. The titer
increased with time after immunization. By immunofluores-
cence of renal biopsies mesangial deposits of rat IgG were
present at weeks 1 and 2. By weeks 2 to 3, linear deposits of rat
IgG were present along the GBM (Fig. 2 A,B,C). In the initial
biopsies the deposits were very fine, lacy, and quite linear and
characteristic of the deposits seen with passive administration
of heterologous antibody or with classic Steblay nephritis. By
week 3 IgG deposits were uniformly present in all rats as well as
being present in some crescents and in insudative lesions (Fig.
2). These deposits increased in intensity and were associated
with more severe insudative lesions with time as the lesion
progressed. Complement deposits were not different from con-
trols and consisted of focal and segmental tubular deposits as
seen in naive rats.
Staining for fibrinogen at week zero was negative. At two to
three weeks small focal and segmental glomerular deposits of
fibrin were observed in 10 to 15% of glomeruli (Fig. 2 D,E, F).
The distribution and number of involved glomeruli with intense
fibrin staining increased over the next several weeks to 30%,
50% and 80% of glomeruli involved. There were increasing
amounts of fibrinogen staining within each glomerular tuft and
within crescents as well as an increase in the number of
glomeruli involved. The intensity of fibrin staining, even at
week 2 was 3+, quite intense, and was 3 to 4+ thereafter. Later
in more severe lesions fibrin appeared in tubular lumens as well
as in glomeruli. Some glomeruli were necrotic and/or encom-
passed with crescents.
No histologic abnormalities were detectable by light micros-
copy at weeks 1 or 2 in any of the animals. By week 3 (Fig. 3A)
an increase in mesangial cellularity was observed. This in-
creased very rapidly in intensity over the next weeks, evolving
into a severe exudative and proliferative GN with crescents.
Mitotic cells as well as segmental necrosis and fibrin deposits
were seen in H&E stained sections. Most animals had no
interstitial infiltrate in the initial biopsies and only minimal
interstitial infiltrates were present even with severe glomerular
disease. By eight weeks (Fig. 3B) severe glomerulosclerosis and
obsolescence of glomeruli had occurred. This was associated
with intense interstitial fibrosis and tubular atrophy, now with
interstitial mononuclear cell infiltrates.
By electron microscopy, rats with GN had extensive foot
process obliteration. There were associated fibrin tactoid de-
posits, and numerous macrophages were present within glomer-
ular crescents and occasionally in the glomerular tufts (Fig. 4).
Mononuclear cells with the morphologic appearance of lympho-
cytes were observed frequently in the lesions and multinucle-
ated giant cells were present within the crescents.
By week 3 abnormal urine protein excretion was present in
most animals immunized with csGBM in acid (Fig. 5). This
increased rapidly with time and was associated with increasing
severity of proliferative lesions. The urinary sediment in ani-
mals with GN showed active components with red cells, white
cells, and red cell casts. The degree of proteinuria increased
with time throughout the period of the study and was associated
with the appearance of lipidemia in some plasma samples. No
abnormal proteinuria was detected in any of the control animals
throughout the period of study. The serum creatinines in EAG
rats increased from 0.52 0.05 at two weeks, to 0.95 0.15 at
four weeks, to 1.16 0.20 mg/dl at the six week bleed (P <
0.01, 4 and 6 week vs. 2 week). These findings were consistent
with the morphologic associates of proliferative GN and gb-
merular sclerosis, and similar to functional changes observed in
humans [1]. EAG rats lost weight, appeared less healthy, had
lack-luster fur, and clinically displayed lassitude and decreased
motor activity. None of the control rats showed any of these
abnormalities and maintained their normal growth patterns.
During the first three weeks of the study, the kidneys appeared
to be of normal size and texture as well as coloration at the time
of biopsy. As GN developed, the kidneys were observed to be
pale and mottled with a cobblestone appearance. The open
biopsies which characteristically bleed briskly initially, did not
bleed readily and upon opening the abdomen for renal biopsy,
clear ascites and granuloma-like lesions were occasionally
noted.
Experiment 3—Effect of acid/antigen immunization on EAG
induction. The original basis for our immunization of animals
with GBM in acid was the hypothesis that exposure of the
nephritogenic antigen by conformational changes might result
in increased antigenicity and enhance the likelihood of inducing
GN. This experiment was designed to investigate this further.
An additional group of six WKY rats were immunized by
exactly the same regimen utilized to induce EAG described
above. Twenty micrograms of csBGBM was used but was
prepared and administered at pH 7.2 rather than in acid.
Animals were followed serially for eight weeks for the appear-
ance of proteinuria which characteristically begins by three
weeks in animals immunized with antigen in acid. However, by
the end of the experiment no abnormal proteinuria had been
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Fig. 2. EAG kidney sections stained for rat IgG (A,B,C) and fibrinogen (D,E,F). Linear GBM deposits are illustrated in (A), insudative lesions in
(B) (arrow) and deposits within a crescent in (C) (an-ow). Fibrin deposits increased, involving 20% of glomeruli at 3 weeks (D), 50% at 4 weeks
(E), and most glomeruli by 6 weeks in (F) X 160.
detected in any of the animals or in controls. Rats were
sacrificed after the eighth week. Histologically there were no
abnormalities by light microscopy. However, distinct linear
deposits of rat IgG were present along the GBM in a pattern and
distribution comparable to that seen in animals immunized with
GBM in acid. Furthermore, circulating anti-GBM antibody was
present by ELISA in titers not significantly different from rats
with EAG (Fig. 1). In addition, titers in EAG and BN rats after
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Fig. 3. A. Photomicrograph of 2 glomeruli
from an open renal biopsy obtained 3 weeks
after a single immunization of an EAG rat
showing poliferation of tuftal cells
accompained by well developed cellular
crescents. PAS, x350. B. Biopsy from EAG
rat 8 weeks after receipt of a single injection
of csBGBM in 0.1 M acetic acid.
Glomeruloscierosis and scarring are evident
with associated tubular dilatation, interstitial
fibrosis, and protein casts. H&E, x350.
immunization by the same regimen in acid were comparable
[WKY, 1.54 0.04 (4) vs. 1.37 0.15 (5), BN], as were WKY
and BN rats immunized with sonicated GBM [WKY, 1.23
0.10(4) vs. 1.10 0.11(4), BN]. Yet only WKY rats immunized
in acid developed GN. Blast transformation studies performed
on spleen cells in quadruplicate from animals immunized at pH
7.2 revealed no response to csBGBM, (see Table 3 in Experi-
ment 4). Thus, the pH of the inimunogen appears not to
influence the ability of the animal to make antibody to the
antigen, but does influence development of the proliferative
lesion and proteinuria in this model.
Experiment 4—Studies of cell mediated i,n,nunity. Some
animals from the second experimental study and other animals
immunized by the same regimen were utilized for the present
studies. Tests for DTH utilizing increments of ear thickness to
csBGBM in acid versus acid vehicle were positive by one to
two weeks after immunization (Table 2). There was no incre-
ment when antigen was given at pH 7.2 or if given to control
animals. KLH immunized rats, as positive controls, showed
comparable increments while naive control animals did not
demonstrate significant increments. BN rats, while not devel-
oping GN, did have positive DTH to csBGBM. To show that
the DTH was mediated by T cells, local adoptive transfer of
DTH was examined. 1.3 X iO nylon wool adherent or non-
adherent splenocytes were mixed with PBS with or without 100
sg csBGBM in 100 sl and injected into foot pads of naive rats.
No increment was observed with either population of cells in
PBS, or adherent cells with antigen. Nylon wool non-adherent
T cells with antigen induced increments of 16.2 2.8 x 10
inches.
Draining popliteal lymph node cells or spleen cells were
cultured in quadruplicate for three or five days with antigen,
Con A or medium and showed a dose dependent antigen-
specific increase in thymidine incorporation (Fig. 6). Nylon
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Fig. 4. Electron micrographs of EAG rats showing (A) extensive foot process obliteration, (B) a crescent containing macrophages, with
phagolysosomes adjacent to Bowman's capsule basement membrane, (C) a probable lymphocyte within a crescent, and (D) a multi-nucleated giant
cell within a crescent. Five complete and several partial nuclei are seen within the cytoplasm of the giant cell, All photographs X 3,150.
Abbreviations are: BC, Bowmans capsule; CL, capillary lumen; E, epithelial cell; L, lymphocyte; M, macrophage; G, giant cell.
wool non-adherent splenocytes demonstrated a similar antigen
specific response to csBGBM. Depletion of T cells, but not B
cells, abrogated this response to antigen. Although cells from
both WKY and BN rats immunized in acid responded to
csBGBM (Table 3), WKY rats immunized at pH 7.2 did not
demonstrate antigen specific blast transformation. Cells from
WKY rats immunized at pH 7.2 with KLH as a positive control
did respond to the specific antigen. Kidneys with severe EAG
and mononuclear cell interstitial infiltrates from one nephritic
animal were removed and pressed through nylon gauze to
prepare mononuclear cells. After separation of lymphocytoid
cells by Ficol-Hypaque, numerous mononuclear cells were
present in suspensions. Many of these were very large, blasto-
cytoid in appearance, and some cells in suspension were
binucleate with indented cytoplasm suggesting they were divid-
ing. Other cells appeared to be lymphocytes with indented
nuclei. Cells obtained from nephritic kidney were cultured with
Con A and showed a stimulation index of only two with basal
counts greater than 3,000 cpm indicating that cells were already
activated with little augmentation with Con A. No cells were
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Immunization
group
Antigen
csBGBM in
acid
csBGBM
pH 7.2 KLH
WKY, acid 12.6 1.4 (11) 1.8 0.4 (4)
WKY, pH 7.2 1.7 0.7 (4)
BN, acid 11.1 1.0 (4)
WKY, KLH 9.9 0.3 (2)
WKY, control 1.8 0.4 (4) 2.5 0.5 (3)
obtainable from control rat kidneys for study in vitro. This was
not unexpected as phenotypic analysis showed essentially no T
cells present in glomeruli or interstitium in normal rats.
Phenotypic analysis. Tissue sections examined by indirect
immunofluorescence with MAb demonstrated T cells, CD4
cells, and leukocyte common antigen positive cells in glomeruli
and crescents. Numerous macrophages were also present.
There were rarely detectable CD8 cells and B cells within the
lesions. Examination of normal kidneys revealed only occa-
sional macrophages and no T or B cells.
In the serial studies, normal rats, control and one week EAG
animals had only rare interstitial macrophages and occasional
rare glomerular macrophage. No lymphocytes were seen. There
were no differences in control animals even up to eight weeks.
Stains for Ia showed 0 to 1 cells/glomerulus and rare interstitial
cells in controls up to eight weeks and in one week EAG rats.
In EAG rats by two weeks occasional glomeruli showed T cells;
Ia cells were 0 to 2/glomerulus; 25% of glomeruli showed 1 to
3 macrophages per glomerulus. By week 3, Ia interstitial
patches of cells were present as were patches of segmental
glomerular Ia cells, up to six per glomerulus. The glomeruli
contained 0 to 2 T cells with some containing up to four T cells.
Immunization
group
Stimulus
Con A, SI csBGBM, SI KLH, SI
WKY, acid 9,66
(39,073 1,886)
7.70
(31,145 3,742)
WKY, pH 7.2 5.51
(4,537 683)
0.76
(629 189)
BN, acid 7.15
(5,903 652)
6.09
(5,034 309)
WKY, KLH 59.91
(85,521 4,573)
28.82
(40,187 2,278)
Half the rats had 0 to 1 CD4 cells/glomerulus. No CD8 or B cells
were seen in glomeruli and only rarely in the interstitium.
Macrophages were present in clusters in glomeruli correspond-
ing to the segmental distribution of fibrin deposits. The most
severe lesions with the largest increase in Ia cells in glomeruli
and interstitium, segmental patches of macrophages, and T cells
occurred at three to five weeks when the proliferative lesion
was maximal. However, patches of cells in the interstitium and
in segmental glomerular lesions with 0 to 2 T cells and patches
of Ia and macrophage cells persisted through the eighth week.
The appearance of cellular components was associated with
increased staining for OX-7, mesangial matrix, at all times,
suggesting a component of endogenous proliferation. Further,
the segmental glomerular lesions were frequently anatomically
related to the location of periglomerular interstitial infiltrates. It
should be noted that infiltrates of cells were present by two
weeks when antibody was not detectable in the circulation or
bound to glomeruli. Rats with GBM bound antibody but no
proteinuria or GN histologically were phenotypically compara-
ble to controls.
Experiment 5—Passive transfer studies. Transfer of 1, 10,
and 60 mg of high titer anti-GBM IgG from nephritic to naive
0 0 + + + + + 30
20
10
GN: 0
(4) (4) (4) (4) (4) (4) (4) (4)
120
100
80
Time, weeks after immunization
Fig. 5. Time course of EAG in WKY rats immunized with csBGBM in
acid. The presence or absence of ON is noted as well as the total
urinary protein and number of animals for each time point. Proteinuria
begins between weeks 2 and 3 coincident with the development of EAG
histologically. Symbol (---) is normal range.
Table 2. DTH reactions
0Fx
a-
C)
Coflagenase digested GBM, pg/mi
Fig. 6. Antigen specific response of EAG rat mononuclear cells to
csBGBM. Similar responses were present with human and rat antigen.
Table 3. Blast transformation studies
0 1 5 10 50 100
Rats immunized with csBGBM in acid or at pH 7.2, or KLH, had
increments in ear thickness vs. vehicle controls using a spring loaded
micrometer measured 24 or 48 hr after antigen administration. Data are
expressed as inches x l0.
a p < 0.01 vs. controls, WKY pH 7.2, and csBGBM, pH 7.2
Animals were immunized with csBGBM in acid or at pH 7.2, or
KLH. Spleen cells were stimulated in quadruplicate with Con A, 4
gIml, csBGBM, 100 sg/ml, or KLH, 50 g/ml, respectively. Data are
expressed as stimulation index, SI, for comparison of responses in
different experiments. CPM are provided in parenthesis.
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rats resulted in linear fixation of antibody on the GBM but no
proteinuria or ON up to the time of sacrifice after four weeks.
Experiment 6—Glomerular bound anti-GBM antibody. The
ELISA absorbance values at 405 nm for the blank (0.066),
normal rat serum (0.083), and eluate of normal glomeruli
(0.059), were not different. The values for eluates of EAG-
WKY (0.292) and BN rats immunized with csBGBM (0.400)
were positive for anti-GBM antibody. When eluate activity was
expressed relative to number of glomeruli, there were 12.3 Xl0 U/glomerulus, normal rats; 83.4 x 10 U/glomerulus,
EAG-WKY rats; and 80.0 x l0 U/glomerulus for BN rats
immunized with csBGBM.
Discussion
Numerous investigators have attempted to establish models
of proliferative EAG. The original model was described by
Steblay, who immunized sheep with multiple doses of glomeruli
in CFA [4]. These animals received hundreds of milligrams of
antigen and developed severe proliferative GN over months
with circulating and bound antibody to the basement mem-
brane, proteinuria, and uremia. However, immunization of
most species including rats, rabbits, dogs, guinea pigs, and
mice, causes circulating and bound antibody to GBM and
frequently proteinuria, but not proliferative GN and decreased
function [5—13]. In each species in which Steblay nephritis has
been induced, multiple immunizations have been required to
induce the lesion, and months to years ensue before develop-
ment of proteinuria, if it occurs at all. The present model
requires only microgram amounts of antigen given once and
disease is detectable in all animals within a few weeks.
Shibata and Nagasawa immunized rats with a glycoprotein
antigen found in multiple organs and produced mesangial pro-
liferative GN, not Steblay nephritis [20]. Sado et al utilized the
method of Shibata and isolated an antigen with characteristics
of collagen [21]. Immunization of animals resulted in linear
GBM deposits and proteinuria with some pulmonary hemor-
rhage. As little as 100 pg of antigen could induce GN although
much larger quantities were needed to produce significant
proteinuria. Only a few animals had abnormal renal function. It
is not clear that this is the same model as Steblay nephritis since
antigen was present in multiple organs (see below). It is also not
clear whether progressive renal failure developed and no infor-
mation was provided about phenotypic analysis of cells that
might be involved or information about cell mediated immunity.
More recently these investigators have described production of
an EAG model similar to that described here, and provided
evidence that the Goodpasture's epitope may be involved [22].
We and others have utilized Engelbreth-Holm-Swarm (EHS)
tumor or the non-collagenous domain, (NC1) of EHS type IV
collagen to immunize animals which consequently developed
circulating antibody to basement membrane [23—25]. Immuni-
zations have been at physiologic pH and in acid. Linear
deposits develop along the glomerular and lung basement
membranes and administration of immune serum intravenously
showed rapid binding to lung and kidney basement membrane.
Despite the presence of antibody, no proteinuria and no prolif-
erative nephritis developed. Of importance is the fact that EHS
type IV collagen does not contain the a3 chains which carry the
Goodpasture's epitope [26]. Weber et al reported in abstract a
model similar to the one described here but in rabbits. Infor-
mation about the time course and other information about the
model remains to be published [27]. More recently, dimers of a3
but not other dimers of type IV collagen have been used to
induce GN in rabbits, supporting a3 as containing the crucial
antigen [28].
Thus, in summary it appears that immunization of a variety of
species and strains of mammals with GBM results in the
development of anti-GBM antibody, sometimes with protein-
uria. Other than in sheep, sporadic, unpredictable and late or no
proliferative lesions develop. The occurrence of similar depos-
its in animals immunized with EHS antigen which does not
contain the Goodpasture's antigen suggests that many Steblay
models result from the formation of antibody against non-
nephritogenic antigen with harmless deposition in the GBM.
We describe here the reliable and reproducible production of
EAG in an inbred mammalian species. This GN was associated
with glomerular hypercellularity, fibrin and crescents as seen in
GN in humans [1, 2]. This is an autoimmune GN, since an
autoimmune process initiated by immunization caused GN, and
no exogenous planted antibody or antigen was required. It is
analogous to human ON initiated by infection or other immu-
nostimulatory event where self tolerance is lost.
In our studies, BN rats developed acute interstitial nephritis
with giant cells and mononuclear cell infiltrates as described in
rats immunized with TBM antigens [29]. This may be attribut-
able to small amounts of contamination with tubular elements
present in all glomerular preparations or cross reactive
epitopes. No histologic abnormalities were found in glomeruli
in contradistinction to other reports that immunization of BN
rats with GBM antigen caused proliferative GN [30]. All of the
animals, both BN and WKY, developed circulating and bound
antibodies to GBM and TBM. These findings are consistent
with previous studies showing that immunization of mammals
with various types of GBM results in the formation of antibody
[5—13]. WKY rats immunized with sonicated GBM did not
develop histologic lesions or abnormal proteinuria—just anti-
body. Only the third group of WKY rats immunized with
csBGBM in acid developed proteinuria, decreased function,
and severe proliferative ON.
The results of our first study led us to perform more detailed
studies. As observed in the first study, WKY rats immunized
with antigen in acid very quickly developed circulating anti-
GBM antibody with deposits along the basement membrane,
proteinuria, and proliferative ON within a few weeks of immu-
nization. We have repeated this immunization procedure in
more than 150 rats and shown that it reproducibly and reliably
results in this clinicopathologic pattern in 100% of immunized
animals.
The lesion was associated with the deposition of IgG and
fibrin as seen in severe necrotizing proliferative GN in humans
[1, 311. The IgG deposits were linear, as described in Goodpas-
ture's syndrome, and then became insudative in nature, also as
described in severe Goodpasture's lesions. These changes have
not been previously described in animal models. Fibrin deposits
in glomeruli correlated with areas of focal proliferation and
necrosis and increased with time. The mechanism by which this
occurred remains to be determined. However, it is known from
nephrotoxic nephritis models that macrophages are attracted to
glomerular lesions, express tissue factor neoantigen and initiate
Bolton et al: Mode! of glornerulonephritis in rats 303
local coagulation [32]. Depletion of macrophages or defibrina-
tion results in amelioration of the lesion and abrogation of
proteinuria [33, 34]. Similar mechanisms have been invoked to
explain human crescentic GN [35]. Since we observed lympho-
cytes and macrophages in lesions at a very early time, it is
possible that similar mechanisms are involved in our model.
While we did not examine animals for evidence of diffuse
intravascular coagulation, the lesions observed in kidney and
lungs (data not shown) are different from those of the general-
ized Shwartzman type [36]. Thus, it seems likely that fibrin
deposition occurred locally, probably mediated by cellular
mechanisms resultant from activated macrophages. Alterna-
tively, platelets and platelet factors may be involved in devel-
opment of these histologic lesions [37, 38]. Further studies will
be needed to clarify this.
Although intense deposits of IgG and fibrin were observed,
there was no increased staining for C3 other than that seen
normally in rats. None of the control animals developed any
antibody or had any deposits of fibrinogen. The normal back-
ground staining for rat C3 was present. Although we did not
measure serum complement or complement activity, the lack of
deposits suggests that complement is not involved in the lesion.
The histologic lesions developed very quickly and progressed
rapidly to glomerulosclerosis, interstitial fibrosis, and scarring.
By eight weeks significant scarring and histologic damage were
present similar to that seen in rapidly progressive GN (RPGN)
in humans in which irreversible scarring can develop in a few
weeks. While the mononuclear interstitial infiltrates were ini-
tially unimpressive, these rapidly developed so that by eight
weeks the GN was associated with intense mononuclear cell
infiltrates in the interstitium also as observed in human disease
[311.
The ultrastructural lesions observed in the present model
were striking and similar in many respects to those seen in
human disease and not previously described in animal models
of EAG [1]. Macrophages, lymphocytoid cells, and polymor-
phonucleocytes were easily demonstrated within the glomerular
tuft and crescents. Fibrin deposits were present in glomeruli
and crescents and we observed multinucleated giant cells within
crescents as has been reported in patients with RPGN. The
formation of these multinucleated giant cells provides strong
evidence for a role for cell mediated immunity in the develop-
ment of the lesions [311. Indeed, the histologic characteristics
were quite reminiscent of DTH reactions and analogous to
certain types of human GN.
The clinicopathologic correlates for ON in this animal model
also paralleled those seen in humans. The development of
proteinuria was brisk and predictable, the urinary sediment
contained red cells, red cell casts and other formed elements as
seen in GN in humans, and red cell casts were apparent
diffusely throughout biopsies in animals with ON. Progression
of the disease was associated with decreased renal function and
nephrotic syndrome with rats developing lipemic plasma sam-
ples, ascites, and wasting. While the latter may be related to the
malnutrition and protein loss, it is also conceivable that cyto-
kines, specifically tumor necrosis factor, may be involved in
this process [39]. The mechanisms responsible for proteinuria in
this model remain to be elaborated. A complex interplay of
factors has been shown to be responsible for proteinuria in
other models [reviewed in 40]. These include GBM pore size
and charge alterations, hemodynamic perturbations, cytokines,
eicosanoids, and other soluble mediators, reactive oxygen
species, as well as structural and functional changes in GBM
and resident glomerular cells. Some of these alterations have
been documented in humans. Further studies will be necessary
to define the mechanisms in the present model and to compare
these to other models and to human disease. This will be
especially important in this model because of its unique char-
acteristics and similarities to human disease.
The induction of GN related to anti-GBM antibodies has been
considered to result from deposition of antibodies along the
GBM. In nephrotoxic nephritis very small quantities, 5 jg/g
kidney tissue, result in GN and there is a dose response
between the amount of heterologous nephrotoxic serum admin-
istered and the severity of the resultant GN [41]. Steblay
nephritis has long been considered an antibody mediated lesion.
However, despite the ease with which antibody to GBM can be
produced in various animal species with various types of
basement membrane, it has been extremely difficult to induce a
proliferative GN in this model other than in sheep.
While small amounts of heterologous antibody produce GN,
extremely large amounts of homologous antibody (up to 30-
fold) are required to transfer Steblay nephritis, and the disease
is only transient and mild despite the presence of antibody along
the GBM [42, 43]. Only in those situations where cells have
been available to induce the lesion, have attempts to transfer
disease been transiently successful [44]. We were unable to
transfer the disease with antibody derived from the serum of
nephritic rats, despite fixation to the GBM. Sado, Naito and
Okigaki reported the transfer of a urinary substance with
characteristics of IgG, but noted an inability to obtain sufficient
antibody from renal eluates or serum [45]. Numerous autoim-
mune organ-specific diseases are associated with the formation
of circulating antibodies but cell mediated immunity is the
major pathogenetic effector system. These models include
tubulointerstitial nephritis, thyroiditis, hepatitis, orchitis, ex-
perimental allergic encephalomyelitis, and diabetes [20, 46—56].
The present studies suggest that cell mediated immunity may
participate in the pathogenesis of the lesion in the present
model. First, immunization with GBM resulted in antibody
formation in both BN and WKY rats regardless of immuniza-
tion schedule, and there was deposition of antibody on the TBM
and GBM. However, GN did not develop unless antigen was
suspended in acid. Secondly, as described above, antibodies
can be easily produced in this model but are generally not
associated with GN. Third, administration of IgG from EAG
sera to naive rats resulted in fixation of antibody on the GBM
but no proteinuria or ON. Fourth, there was no association
between the presence or intensity of the GBM deposits and the
severity of the GN. Fifth, activation of the cell-mediated
immune system was present as evidenced by DTH reactions to
the immunizing antigen as compared to controls, and by in vitro
blast transformation to antigen. Sixth, components of the
cellular immune system were present in the lesions by pheno-
typic analysis, and morphologic findings were consistent with
cellular immunity with macrophages, lymphocytoid cells, and
multinucleated giant cells. Seventh, nephritic rat kidneys con-
tained a mononucleocyte infiltrate which appeared to contain
actively dividing lymphocytes, not present in normal rat kid-
neys. Additionally, previous work has demonstrated that EAG
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produced in a non-mammalian species, the chicken, cannot be
transferred with passively administered antibodies, is not asso-
ciated chronologically with the appearance or intensity of
antibody fixation to the basement membrane, and can be
induced in animals which do not make antibody to the immu-
nizing antigen [14, 16, 21, 57]. Finally, transfer of sensitized
cells from chickens immunized to GBM results in the develop-
ment of GN in naive recipients [211. Further studies will be
needed to delineate whether cells are involved in the pathogen-
esis of the present mammalian model as ancillary components
or as a major effector mechanism.
BN rats immunized with the identical regimen which induced
EAG in WKY rats had circulating and bound anti-GBM anti-
bodies, demonstrated DTH, and had antigen specific blast
transformation as seen with WKY rats. Yet they did not
develop GN. WKY and BN sera contained comparable levels of
antibody to the putative Goodpastures antigen as shown by
ELISA allegedly specific for the antigen (Scimedx, Denville,
New Jersey, USA; WKY 0.72 0.09 vs. BN 0.89 0.30 units).
No differences in quantity of glomerular bound antibody were
observed between BN and WKY rats, and BN rats immunized
with GBM clearly can develop characteristic linear GBM
deposits without proteinuria or proliferation [58]. Both the
antibody and the cellular response to a nephritogenic antigen
are influenced by the immunogenetic environment resulting in
strain specific differences in development of GN to a given
stimulus [59]. It is possible that the BN T cell receptor reper-
toire lacks specificity for the nephritogenic epitope(s) despite
mounting an immune response to other components of the
immunogen or that the nephretogenic epitope is absent in BN
kidneys. The failure of BN rats to develop GN remaines to be
clarified.
Despite previous failures to induce proliferative GN in many
species, recent work identifying the Goodpasture's antigen led
us to utilize a new approach to induce GN in rats. In Goodpas-
ture's syndrome antibodies are formed to various components
of the GBM but most notably to components of type IV
collagen [60, 61]. Type IV collagen is the major structural
component of basement membranes and generally consists of
two genetically defined alpha chains in a triple helix structure
[60, 62]. Certain basement membranes, specifically human,
bovine and rat contain not only al and a2 chains but also a3, a4
and a5 chains [60, 63, 64]. In addition, the NC! domain of the
a3 has been shown to contain the putative Goodpasture's
antigen [63, 65—671. This epitope is present in basement mem-
branes of the kidney, eye, and ear, appears to be sequestered
under normal physiologic conditions, and is reversibly exposed
by maneuvers which denature the protein such as suspension in
acid, 6 M urea, or 6 M guanidine [65, 68]. For these reasons we
decided to utilize an immunization protocol which would theo-
retically allow exposure of the antigen. As demonstrated in the
present manuscript, immunization with very small amounts of
csGBM in acid did indeed result in GN. In experiment 4 we
performed studies to further define the importance of the acid
milieu. None of the animals immunized by our usual protocol,
but at physiologic pH rather than in acid, developed proteinuria
and no histologic abnormalities were seen by light microscopy.
However, animals immunized with GBM at normal pH did
develop circulating antibodies detectable by ELISA, and had
antibodies deposited along the GBM. Blast transformation
studies in vitro utilizing cells derived from pH 7.2 antigen
immunized animals were unresponsive to GBM antigen. Fur-
thermore, EAG rats responsive in DTH tests to antigen/acid
had no response when antigen was given at 7.2. These studies
suggest a disparity between the epitope responsible for the cell-
mediated immune response, GN, and formation of antibody in
the circulation. It further suggests that the epitope(s) responsi-
ble for induction of GN may be different from the one(s)
responsible for formation of circulating antibodies. This is also
suggested by failure to produce GN by GBM immunization
under routine conditions, which generally results only in anti-
body formation [5—13]. The present model appears to have
direct significance relative to understanding pathogenetic mech-
anisms in human disease associated with antibodies against the
GBM. The clinical spectrum of these entities can range from
asymptomatic disease to mild focal GN to devastating RPGN
and Goodpasture's syndrome [1, 2]. The latter are associated
with renal infiltration with large numbers of CD4 cells and
macrophages [31].
In vitro assays with GBM antigen and cells from patients
provide additional support for cell mediated immunity in patho-
genesis [66—7!]. The histologic appearance of the present GN,
the development of interstitial infiltrates, the phenotypic anal-
ysis of the biopsy, the segmental necrosis and crescents ob-
served in the present model, proteinuria, and the rapid progres-
sion toward chronic renal scarring are all remarkably analogous
to the situation seen in anti-GBM disease in humans. In
humans, as in Steblay nephritis, the association and coopera-
tion between the cellular and antibody system remains to be
elucidated [72, 73]. Despite the presence of circulating antibod-
ies, some patients do not develop clinical disease. Patients with
progressive disease leading to renal failure and transplantation
may not develop recurrent disease despite recurrent antibody
formation, and patients with Alport syndrome who lack the
putative antigen can develop circulating antibodies which de-
posit on the basement membrane and may or may not have GN
[74—76]. Why some patients have antibodies without disease
and others develop disease is unclear. The present model
suggests that cell mediated immunity may play a role in
determining the clinical expression consequent to sensitization
to basement membrane, but the mechanisms remain to be
determined. It is possible that certain epitopes elicit an antibody
response resulting in GBM deposits without proliferation, while
others produce a species of antibodies that causes proliferation.
Some epitopes might result in the initiation of a cell-mediated
immune response, either in collaboration with the antibody
response or alone, which results in the phenotypic expression
seen by the clinician. Clearly any approach to therapy depends
upon the pathogenetic mechanisms involved. A model has not
been available to examine the pathogenesis of this lesion since
a reliable, reproducible, experimental GN closely analogous to
the human disease had not been developed in an inbred mam-
malian species. The present model of EAG in WKY rats,
however, appears to be such a model and should lend itself to
further examinations of the pathogenetic events involved in the
development of proliferative GN, hopefully with direct appli-
cability to the human counterpart.
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